Business Wire

AIOSYN

14.3.2023 13:01:37 CET | Business Wire | Press release

Share
Aiosyn Launches AI-powered Automated Quality Control to Improve the Digital Pathology Workflow

Aiosyn, a software company that develops AI-powered pathology software, has launched its first product that assists digital pathology labs across research, diagnostics and pharma to improve their quality control (QC) process. AiosynQC is an AI-powered algorithm that automatically scans for the most common artifacts that occur during the heterogeneous pre-analytical process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005006/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Out-of-focus regions of an H&E stained slide image, blurry and difficult to read, are identified and highlighted with Aiosyn's automated quality control powered by AI. (Photo: Business Wire)

The algorithm of AiosynQC is trained on hematoxylin and eosin (H&E) stained slides. The product helps labs to ensure that only high-quality images are used by pathologists, technicians, and researchers. It can flag cases before presentation to a pathologist, thereby improving the efficiency of the digital pathology workflow by reducing the time that is currently used to manually check for artifacts in whole slide images.

AiosynQC is a modular and flexible software offered as a service solution that can be integrated into existing digital pathology software and deployed through the cloud or on-premise installation. The automated QC is the first product in Aiosyn’s workflow solutions suite. It will be part of a portfolio of deep learning algorithms currently in development for different pathologies for which there is a clear need to improve diagnostic precision and quality.

AiosynQC will be an important foundational layer and we believe that AI-powered workflow solutions are the entry point for the use and adoption of computational pathology algorithms” according to Patrick de Boer, CEO of Aiosyn.

More information about AiosynQC can be found here.

About Aiosyn

Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice. More about Aiosyn can be found here.

AiosynQC

AiosynQC can only be used in the European Union and the United Kingdom. In the EU and the UK, AiosynQC is not considered a medical device under European IVDR and UK MDR 2002 legislation, respectively. AiosynQC is not intended to be used as an accessory to, nor is it necessary to be used in combination with, any AI or other medical devices to specifically enable them to meet their intended purpose or directly assist in their functionality.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005006/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

Hytera Announces 450Connect Whitelisting of PNC660 450MHz at MWC 20266.3.2026 13:02:00 CET | Press release

Hytera, a leading global provider of critical communications technologies and solutions, announced that its mission-critical smart device, the PNC660 450MHz, has been granted whitelist certification by 450Connect during the Mobile World Congress 2026 (MWC26), held from March 2 to 5 in Barcelona, Spain. This certification authorizes the device for full commercial deployment across European 450MHz private broadband networks, marking a significant milestone for Hytera in delivering reliable, secure, and robust communication solutions to energy providers and other critical infrastructure sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305205209/en/ Hytera launches the MCX Smart Device PNC660 450MHz 450Connect is the exclusive licensee and operator of the nationwide 450MHz radio network in Germany and across Europe. Its whitelist program enforces stringent evaluation criteria covering device compatibility, network inte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye